Investing.com - Cellectis reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Cellectis announced earnings per share of $-0.28 on revenue of $27.97M. Analysts polled by Investing.com anticipated EPS of $-0.8133 on revenue of $8.21M.
Cellectis shares are up 4.26% from the beginning of the year, still down 55.26% from its 52 week high of $34.71 set on January 20. They are under-performing the Nasdaq which is up 5.78% from the start of the year.
Cellectis follows other major Healthcare sector earnings this month
Cellectis's report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B.
Pfizer had beat expectations on Tuesday with first quarter EPS of $0.93 on revenue of $14.58B, compared to forecast for EPS of $0.7773 on revenue of $13.67B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar